About the offering
The company is seeking $3 million in pre-launch equity funding, offering a 15% stake at a $20 million post-money valuation. The raise is intended to provide approximately 18 months of runway at an operational burn rate of roughly $167,000 per month through the end of 2026. The platform is scheduled to launch in Q3 2025, with revenue generation expected to begin in January 2026. The company projects $1.5 million in Year 1 (2026) revenue, scaling to $5.6 million by 2028, driven by SaaS subscriptions, clinical partnerships, and B2B licensing. Gross margins are expected to stabilize around 66%, with the business model described as becoming cash-flow efficient early. The company positions itself as a first-of-its-kind 'one-window' platform combining biosensing, genomics, artificial intelligence, and clinical insight. A key feature highlighted is the built-in MedAI Studio, which is described as enabling real-time model evolution by clinicians. The offering is framed as a pre-launch equity opportunity at $2 per share, with the 15% stake open to strategic partners. The company describes itself as regulation-ready, customizable, and scalable, and positions its offering within the AI-powered preventive care space.
FAQ
How much has AICenna raised?
AICenna has raised $4,000 of a $600,000 goal.
Where is AICenna's campaign listed?
The offering is listed on ChainRaise, an SEC-registered Reg CF intermediary.
What are the terms of AICenna's raise?
Membership Units, $19.4M cap, $2.00/share.
When does AICenna's offering close?
The stated close date is Jun 19, 2026.